CRC-001
Colorectal Cancer · MMR/MSI/KRAS Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · GI-ONCOLOGY← RESEARCH
Colorectal Cancer
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
MSI-H → Pembrolizumab KN-177 PROVEN
1st-line mCRC. PFS 16.5 vs 8.2mo. FDA 2020.
Andre 2020 NEJM KEYNOTE-177
KRAS/NRAS WT → Anti-EGFR PROVEN
Cetuximab/panitumumab. Only ~40% mCRC eligible.
Douillard 2013 NEJM panitumumab
BRAF V600E → BEACON PROVEN
Encorafenib+cetuximab. OS 9.0 vs 5.4mo. FDA 2020.
Kopetz 2019 NEJM BEACON
KRAS G12C → Sotorasib+Pani PROVEN
CodeBreaK 300. PFS 5.6 vs 2.2mo. FDA 2023.
Fakih 2023 NEJM
FOLFOX/FOLFIRI+Bev Backbone PROVEN
Non-MSI-H non-actionable standard. Bev adds ~2mo OS.
Hurwitz 2004 NEJM
Open Sorries — Click to Expand
S-1 SORRY-1 · MSS 85% Checkpoint-Resistant
S-2 SORRY-2 · KRAS G12D Undruggable
S-3 SORRY-3 · Liver Metastasis Timing
S-4 SORRY-4 · HER2 Amp Underrecognized
S-5 SORRY-5 · Peritoneal Mets Poor Prognosis
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
CRC-001 · MSI-H → CHECKPOINT · KRAS G12C DRUGGABLE · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693